Is CervoMed Inc. (CRVO) a Buy, Sell, or Hold?
NASDAQ : CRVO
CervoMed Inc.
$3.07 USD
-$0.02 (-0.65%)
- Volume
- 0
- Average Volume
- 5.63M
- Market Capitalization
- $28.42M
- P/E Ratio
- -0.96
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $11.25
- Year Low
- $2.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.57
Company Overview
NASDAQ
John J. Alam
Biotechnology
Healthcare
CRVO
15
US
USD
Liquidity Metrics
0.00
8.57
8.57
7.41
0.00
Sales & Valuation
-$
88.12
1.37
-1.02
-2.73
Profitability
-$2.98
-$26.97M
-9408.76%
-9408.76%
-156.02%
-116.76%
P/E Metrics
-0.96
0.04
0.04
Analyst Price Target & Rating
$9.00
$9.00
$9.00
2/5
7 Analysts
-65.89%
Financial Health Scores
-3.16
2/9
$22.96M
$25.99M
$3.03M
-$30.35M
Key Metrics (TTM)
$6.15M
19.06
-0.20
8.57
-156.02%
-135.73%
-95.87%
-97.79%
0 days
Company Executives
| Name | Title |
|---|---|
| Mark A. De Rosch | Executive Vice President of Regulatory, Government Affairs & Program Management |
| Kelly Blackburn | Executive Vice President of Clinical Development |
| John J. Alam | Co-Founder, Chief Executive Officer, President & Director |
| Marinus Verwijs | Executive Vice President of Technical Operations |
| Claudia Ordonez | Senior Vice President of Medical Science |
| Sylvie L. Gregoire | Co-Founder & Director |
| William Robert Elder | Chief Financial Officer, General Counsel & Corporate Secretary |
| Matthew Winton | Chief Commercial & Business Officer |
Poll Results
No votes yet today — be the first to share your view!
About CervoMed Inc. (NASDAQ:CRVO) Stock
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts. ...
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-10 07:30:00
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15 th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026 Completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million, extending cash runway through the third quarter of 2027 BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the second quarter ended June 30, 2026, and provided corporate updates. “The second quarter was marked by meaningful progress across both our business and pipeline.
2026-08-05 07:30:00
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.
2026-08-04 05:15:00
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines
2026-07-14 07:30:00
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
2026-07-09 07:30:00
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
2026-07-06 07:30:00
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
2026-06-22 16:05:00
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share.
2026-06-18 12:35:00
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions.
Frequently Asked Questions
-
What is the current CervoMed Inc. (CRVO) stock price?
-
CervoMed Inc.(NASDAQ:CRVO) stock price is $3.07 in the last trading session. During the trading session, CRVO stock reached the peak price of $11.25 while $2.13 was the lowest point it dropped to. The percentage change in CRVO stock occurred in the recent session was --0.65% while the dollar amount for the price change in CRVO stock was -$0.02.
-
CRVO's industry and sector of operation?
-
The NASDAQ listed CRVO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRVO?
-
Mark A. De Rosch | Executive Vice President of Regulatory, Government Affairs & Program Management
Kelly Blackburn | Executive Vice President of Clinical Development
John J. Alam | Co-Founder, Chief Executive Officer, President & Director
Marinus Verwijs | Executive Vice President of Technical Operations
Claudia Ordonez | Senior Vice President of Medical Science -
How many employees does CRVO have?
-
Number of CRVO employees currently stands at 15. CRVO operates from 20 Park Plaza, Boston, MA 02116, US.
-
Link for CRVO official website?
-
Official Website of CRVO is: https://www.cervomed.com
-
How do I contact CRVO?
-
CRVO could be contacted at phone #617-744-4400 and can also be accessed through its website. CRVO operates from 20 Park Plaza, Boston, MA 02116, US.
-
How many shares of CRVO are traded daily?
-
The average number of CRVO shares traded daily for last 3 months was 5.63M.
-
What is the market cap of CRVO currently?
-
The market value of CRVO currently stands at $28.42M with its latest stock price at $3.07